Galaxa Pharma a/s: Financial statements 2022
CVR: 41183144
Source: annual report 2022, Danish Business Authority
01/10/2021 – 30/09/2022
Galaxa Pharma a/s (CVR 41183144) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -845,553 and a net result of DKK -2,045,843 compared with DKK -133,658 the year before. Equity in the 2022 report amounted to DKK 814,384. The solvency ratio was 26.5%. The company had 2 employees in the financial year.
- Gross Profit
- DKK -845,553
- Profit/Loss
- DKK -2,045,843
- Equity
- DKK 814,384
- Total Assets
- DKK 3,074,181
- Employees
- 2
Official annual report
Keep an eye on Galaxa Pharma a/s
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of October 25, 2022, Bo Erik Lennart Unéus has left the board of directors of Galaxa Pharma a/s.
As of February 9, 2022, Alexandre Fevre has joined the board of directors of Galaxa Pharma a/s.
About Galaxa Pharma a/s
Galaxa Pharma a/s is a Danish company of the type Aktieselskab based in København Ø, founded in 2020. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named CanNordic A/S. The management consists of Lone Henriksen. The board consists of Gitte Henriksen, Jens Jørgen Hagelskjær and Lone Henriksen. The company is owned by CS MEDICA a/s. The company has 1 employee (2023). In 2025, the company reported a gross profit of DKK -398,874 and a net result of DKK -461,281 compared with DKK -819,815 the year before. Equity in the 2025 report amounted to DKK -209,574.